We are live on ! Find out more
EIGR

Eiger BioPharmaceuticals, Inc.
EIGR

Delisted

EIGR was delisted on the 10th of April, 2024.

Back to rankings

39 hedge funds and large institutions have $68.5M invested in Eiger BioPharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 5 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 5

9% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 11

3% less funds holding

Funds holding: 40 → 39 (-1)

32% less capital invested

Capital invested by funds: $101M → $68.5M (-$32.7M)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
39
Holders Change
-1
Holders Change %
-2.5%
% of All Funds
0.89%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
10
Increased
14
Reduced
5
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
+$1.92M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$976K
3
KCM
Knoll Capital Management
Florida
+$741K
4
Renaissance Technologies
Renaissance Technologies
New York
+$660K
5
BlackRock
BlackRock
New York
+$513K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$5.36M
2
DM
Deerfield Management
New York
-$4.18M
3
SCM
Stonepine Capital Management
Oregon
-$2.09M
4
PM
Prosight Management
Texas
-$1.46M
5
EAM
Eventide Asset Management
Massachusetts
-$611K
Name Holding Trade Value Shares
Change 		Change in
Stake
WS
26
Wedbush Securities
California
$191K +$191K +645 New
Bank of America
27
Bank of America
North Carolina
$180K +$150K +507 +507%
DS
28
DRW Securities
Illinois
$158K +$157K +533 New
Bank of New York Mellon
29
Bank of New York Mellon
New York
$147K +$6.5K +22 +5%
Bank of Montreal
30
Bank of Montreal
Ontario, Canada
$122K +$123K +416 New
Goldman Sachs
31
Goldman Sachs
New York
$116K +$116K +394 New
California Public Employees Retirement System
32
California Public Employees Retirement System
California
$99K – – –
Wells Fargo
33
Wells Fargo
California
$37K +$5.02K +17 +16%
UBS Group
34
UBS Group
Switzerland
$16K +$591 +2 +4%
MAM
35
Meeder Asset Management
Ohio
$5K -$295 -1 -6%
PCTC
36
Perkins Coie Trust Company
Washington
$2K – – –
Citigroup
37
Citigroup
New York
$1K – – –
BNP Paribas Financial Markets
38
BNP Paribas Financial Markets
France
$621 – – –
AC
39
Armistice Capital
New York
– -$5.36M -12,800 Closed
DM
40
Deerfield Management
New York
– -$4.18M -10,000 Closed
SCM
41
Stonepine Capital Management
Oregon
– -$2.09M -5,000 Closed
Millennium Management
42
Millennium Management
New York
– -$520K -1,242 Closed
OAM
43
Oxford Asset Management
United Kingdom
– -$261K -610 Closed
JP Morgan Chase
44
JP Morgan Chase
New York
– -$180K -431 Closed
Deutsche Bank
45
Deutsche Bank
Germany
– -$115K -388 Closed
Barclays
46
Barclays
United Kingdom
– -$55.2K -187 Closed
TRCT
47
Tower Research Capital (TRC)
New York
– -$77K -186 Closed
Macquarie Group
48
Macquarie Group
Australia
– -$10K -23 Closed
CHP
49
Cable Hill Partners
Oregon
– -$4K -8 Closed
1
2

EIGR Hedge Fund Activity: Q1 2018 in Review

39 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q1 2018, worth a combined $68.5M — down 32% from $101M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of EIGR and 10 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 14 added.

The largest buyer was 683 Capital Management, opening a new position worth an estimated $1.92M. The largest seller was Armistice Capital, exiting entirely with an estimated $5.36M sold.

  • 39 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q1 2018, down from 40 in Q4 2017.
  • Funds reported $68.5M of Eiger BioPharmaceuticals, Inc. stock for Q1 2018, down 32% quarter-over-quarter.
  • 10 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q1 2018 and 11 closed out, a net change of -1 holder.
  • The largest Eiger BioPharmaceuticals, Inc. buyer in Q1 2018 was 683 Capital Management, an estimated $1.92M added.
  • The largest Eiger BioPharmaceuticals, Inc. seller in Q1 2018 was Armistice Capital, an estimated $5.36M sold.

Based on aggregated 13F filings for Q1 2018.